Spots Global Cancer Trial Database for met
Every month we try and update this database with for met cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140 | Colorectal Neop... | Gene mutations ... | 18 Years - | Istituto Clinico Humanitas | |
| A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients | NCT03047837 | Tertiary Preven... | ASA MET Placebo | 18 Years - 80 Years | Ente Ospedaliero Ospedali Galliera | |
| A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors | NCT00742261 | Solid Tumours | GSK1363089 | 18 Years - | GlaxoSmithKline | |
| GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | NCT05316935 | Endometrial Neo... Atypical Endome... Progesterone Re... | GnRHa Letrozole 2.5mg Diane-35 MET | 18 Years - 45 Years | Fudan University | |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | NCT05456256 | Adenocarcinoma ... Carcinoma, Non-... | LP-300 Pemetrexed Carboplatin | 18 Years - | Lantern Pharma Inc. | |
| Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | NCT04270591 | C-Met Exon 14 M... | Glumetinib | 18 Years - 80 Years | Haihe Biopharma Co., Ltd. | |
| A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors | NCT00742261 | Solid Tumours | GSK1363089 | 18 Years - | GlaxoSmithKline | |
| Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | NCT04270591 | C-Met Exon 14 M... | Glumetinib | 18 Years - 80 Years | Haihe Biopharma Co., Ltd. | |
| GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | NCT05316935 | Endometrial Neo... Atypical Endome... Progesterone Re... | GnRHa Letrozole 2.5mg Diane-35 MET | 18 Years - 45 Years | Fudan University | |
| The Effect of a Liraglutide on IVF in Obese PCOS | NCT03353948 | Polycystic Ovar... Obesity Infertility, Fe... | MET COMBI | 18 Years - 37 Years | University Medical Centre Ljubljana | |
| A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC | NCT04606771 | Non-Small Cell ... | Osimertinib + S... Savolitinib + P... | 18 Years - | AstraZeneca | |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | NCT05110196 | Non-Small Cell ... | Capmatinib 150 ... Capmatinib 200 ... | 18 Years - 99 Years | Novartis | |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | NCT05110196 | Non-Small Cell ... | Capmatinib 150 ... Capmatinib 200 ... | 18 Years - 99 Years | Novartis | |
| A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma | NCT04533321 | Squamous Cell C... | Afatinib | 21 Years - 99 Years | National University Hospital, Singapore | |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140 | Colorectal Neop... | Gene mutations ... | 18 Years - | Istituto Clinico Humanitas |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
